Recent and retrospective studies have shown that decreased wild type CD82 expression could be a useful marker for metastatic and has invasive potential in some human tumor types, including pancreatic, breast, colorectal, bladder and oral cancers[17-23]. The gene discussed is CD82; the disease is neoplasm.